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Major	advances	 in	anticancer	medical	 therapies	
have	been	performed	in	last	decades,	and	the	poten-
tial	impact	on	survival	of	the	new	chemotherapeutical,	
anti-angiogenic	and	biological	molecules	had	been	
clearly	discussed	in	literature.
Despite	the	availability	of	new	therapeutical	agents	
is	quite	homogeneous	among	 the	 two	continents,	
comparison	of	SEERS	and	EUROCARE	databases	
evidenced	US	vs.	European	cancer	survival	advan-
tages,	particularly	when	colorectal	malignancies	were	
considered	[1,	2].	Correction	 for	stage	at	diagnosis	
consistently	 reduced	colorectal	survival	differences	
and	the	reduction	was	substantially	unrelated	to	the	
European	geographic	area	analyzed,	 thus	confirm-
ing	that	treatment	modalities	may	be	almost	uniform	
between	the	two	continents.	
Since	early	diagnostic	procedures	might	be	much	
less	available	in	Europe	than	in	USA	[1],	the	presence	
of	 a	 diagnostic	 screening-related	bias	was	hypo-
thesized	to	explain	the	observed	survival	difference.	
Deficiencies	in	European	cancer	screening	guideline	
implementation	and	 inadequacy	of	 screening	 test	
advising	in	primary	care	setting	have	been	highlighted	
in	literature	[3–9].	
Monitoring	of	early	diagnostic	procedures	is	con-
sequently	required	in	order	to	tailor	a	comprehensive	
European	health-policy	planning.
Furthermore,	the	European	health	sanitary	systems	
are	not	homogeneous	due	to	the	different	economic	
backgrounds	and	 the	different	 languages	spoken	 in	
each	nation.	 In	order	 to	bridge	the	European	cancer	
screening	experiences	in	a	comprehensive	standardi-
zed	survey	of	screening	patterns	an	international	task	
force	was	developed.	All	network	and	project	planning	
was	directed	from	the	PACMeR	of	Athens	(Pan-Hellenic	
Association	 for	Continual	Medical	Research),	and	at	
present	it	involves	14	centers	in	9	European	Nations.	
In	2004	the	group	presented	preliminary	results:	
SESy_Europe	database	 (Screening	Evaluation	Sys-
tem	—	Europe)	[10,	11]	a	multilanguage	3-components	
database	dedicated	to	cancer	screening	monitoring	
among	European	countries.	
Database	is	focused	on	major	“malignant	killers”	and	
preventable	malignancies	(breast,	cervical,	colorectal,	
lung,	urinary	tract,	skin	and	prostate	cancer	early-de-
tection	practices)	and	targeted	to	the	analysis	of	both	
cost-effective	 (e.g.	mammography,	Papanicolaou	
smear,	stool	occult	blood	test)	and	not-recommended	
procedures	(e.g.	full	chest	radiography,	urinalysis).	
Table. Actual profile of Sesy Europe Database: analyzed variables orga-
nized by category (socio-demographic elements, cancer related risk fac-
tors, over-practice patterns, practice patterns); standardized translation in 
10 languages; PHE — Periodic Health Examination
SESy_Europe Database profile
Sociode-
mographic 
elements
Age and gender
Education
Family status
Profession
Provenance
Urban area
Personal 
risks
Body mass index
Cancer family history 
Disease history Gynecologi-
cal profile Height and weight
Insurance coverage
PHE rate
Solitude
Skin type 
Behavioral 
risk fac-
tors
Alcohol
Diet 
Sun exposure
Tobacco
Screening 
over-
practice 
patterns
Blood count
Chest X-Rays
Prostate cancer 
Urinalysis
Screening 
practice 
patterns
Breast cancer
Cervical cancer 
Colorectal cancer
Skin Cancer 
Languages o Bulgarian
o English
o French
o German
o Greek
o Italian
o Polish 
o Romanian
o Russian
o Spanish
o Turkish
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Software	has	already	been	tested	in	Greece	for	its	
feasibility	in	recording	and	data	storing.	A	nationwide	
sample	of	more	 than	6.500	Hellenic	 individuals	had	
been	registered	in	the	database	and	related	data	will	
be	soon	released	to	medical	literature.	Standardized	
pre-codified	translations	(ID-related)	of	2,331	parame-
ters	had	been	adjourned	 for	all	 the	basic	eight	 lan-
guages	of	the	database,	and	translation	in	Bulgarian,	
Polish	and	Russian	has	been	added.	The	database	
had	been	proposed	to	the	Steering	Committee	of	the	
EUROCHIP	 (European	Cancer	Health	 Indicator	Pro-
ject)	[12]	and	it	is	under	evaluation	for	its	application	
in	 the	wider	Europe	(since	the	Panhellenic	Associa-
tion	for	Continual	Medical	Research	PACMeR-ΠΕΔΙΕ	
is	a	non-profit	medical	association,	the	database	will	
be	provided	free	of	charge).	The	actual	profile	of	the	
database	is	presented	in	the	table.	
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